Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Aug;20(8):471-480.
doi: 10.1038/s41568-020-0262-1. Epub 2020 May 13.

p53: 800 million years of evolution and 40 years of discovery

Affiliations
Review

p53: 800 million years of evolution and 40 years of discovery

Arnold J Levine. Nat Rev Cancer. 2020 Aug.

Abstract

The evolutionarily conserved p53 protein and its cellular pathways mediate tumour suppression through an informed, regulated and integrated set of responses to environmental perturbations resulting in either cellular death or the maintenance of cellular homeostasis. The p53 and MDM2 proteins form a central hub in this pathway that receives stressful inputs via MDM2 and respond via p53 by informing and altering a great many other pathways and functions in the cell. The MDM2-p53 hub is one of the hubs most highly connected to other signalling pathways in the cell, and this may be why TP53 is the most commonly mutated gene in human cancers. Initial or truncal TP53 gene mutations (the first mutations in a stem cell) are selected for early in cancer development inectodermal and mesodermal-derived tissue-specific stem and progenitor cells and then, following additional mutations, produce tumours from those tissue types. In endodermal-derived tissue-specific stem or progenitor cells, TP53 mutations are functionally selected as late mutations transitioning the mutated cell into a malignant tumour. The order in which oncogenes or tumour suppressor genes are functionally selected for in a stem cell impacts the timing and development of a tumour.

PubMed Disclaimer

References

    1. Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. & Vogelstein, B. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249, 912–915 (1990). - PubMed
    1. Baker, S. J. et al. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res. 50, 7717–7722 (1990). - PubMed
    1. Olivier, M. et al. The IARC TP53 database: new online mutations analysis and recommendations to users. Hum. Mutat. 19, 607–614 (2002). - PubMed
    1. Olivier, M., Hussain, S. P., Caron de Fromentel, C., Hainaut, P. & Harris, C. C. TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci. Public. 247-270 (2004).
    1. Olivier, M., Hollstein, M. & Hainaut, P. TP53 mutations in human cancers: origins, consequences and clinical use. Cold Spring Harb. Perspect. Biol. 2, a001008 (2010). - PubMed - PMC

Publication types

MeSH terms

Substances

LinkOut - more resources